Julio 2022: On July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing a next-generation chimeric antigen receptor (CAR)-T cell therapy platform targeting solid cancer, announced that they had entered into a strategic partnership MOU concerning the development of a new CAR-T cell therapies. The MOU was in regard to the development of new CAR-T cell therapies. Through the use of this memorandum of understanding (MOU), GenScript ProBio and ACT Therapeutics have come to an agreement to further their collaboration in the field of cell therapy.
ACT Therapeutics y GenScript ProBio están en proceso de firmar un contrato para el desarrollo y producción de plásmidos y vectores de virus para la primera tubería de la plataforma avanzada CAR-T de ACT Therapeutics (plataforma ACT), que también se encargará de producir materias primas. para los proyectos posteriores de ACT Therapeutics. El contrato cubrirá la producción de plásmidos y vectores de virus para la primera tubería de la plataforma CAR-T avanzada de ACT Therapeutics.
Como resultado de este acuerdo, GenScript ProBio ha sido elevado al estado de socio global que puede admitir plataformas ACT para terapias ACT.
La plataforma ACT es una tecnología de terapia génica y celular de próxima generación que se dirige a los antígenos del cáncer mediante la inserción de genes diseñados para atacar esos antígenos en las células inmunitarias. Estos genes se entregan a las células inmunitarias mediante el uso de vectores de virus. GenScript ProBio posee un desarrollo de procesos de vectores de virus de alta calidad y una plataforma de servicio integral para la producción de GMP, los cuales son necesarios para el desarrollo de la terapia celular y génica.
ACT Therapeutics’ ACT platform is an advanced CAR-T technology that has a next-generation structure that goes beyond the second-generation CAR-T cell therapy and targets existing cáncer de sangre. This is accomplished by overcoming the immune suppression microenvironment of solid cancer and activating the immune cells that are surrounding the cancer. Several studies have also used animals to test the ACT platform to see how well it works and if it is safe. These studies have also confirmed that the platform can be used to treat solid cancer while staying in the immunosuppressive environment of that cancer. Additionally, it complements the shortcomings of the existing second-generation CAR-T, which makes it a competitive technology for the treatment of solid cancer.
ACT Therapeutics is a Korean bio venture company that has received initial investment through DAYLI Partners, Korea’s leading bio and healthcare venture capital, since its establishment in 2020, and has been recognized for its technology such as receiving pre-series A investment in Samho Green Investment. DAYLI Partners is Korea’s leading bio and healthcare venture capital since its establishment in 2020. At the moment, investment consultations are being held with various securities firms and venture capital companies in order to entice Series A investment.
Brian H. Min, CEO of GenScript ProBio, said, “We are very happy to cooperate with ACT therapeutics in strategic partnership, and we are looking forward to support ACT Therapeutics’ ACT platform as a global partner through our accumulated technology.”
Seogkyoung-Kong, CEO de ACT Therapeutics, dijo: “Hemos completado los preparativos para que la plataforma ACT surja a nivel mundial a través de una asociación estratégica con GenScript ProBio. Aceleraremos el desarrollo de tratamientos dirigidos a cánceres sólidos refractarios e intratables”.
Acerca de GenScript ProBio
GenScript ProBio is a subsidiary of GenScript Biotech Corporation, proactively providing end-to-end CDMO service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in cell and gene therapy (CGT), vaccine discovery, biologics discovery and antibody protein drug development to accelerate drug development for customers. GenScript ProBio has established companies in the United States, the Netherlands, South Korea, Shanghai, Hong Kong, Nanjing and other places to serve global customers, and supported customers in the United States, Europe, Asia Pacific and other regions to obtain more than 30 IND approvals.
Hacia la misión de "Innovación a través de la colaboración", GenScript ProBio se compromete a ayudar a los clientes a acortar el cronograma para el desarrollo de medicamentos biológicos desde el descubrimiento hasta la comercialización, reduciendo significativamente los costos de investigación y desarrollo y construyendo un futuro más saludable.
